依诺沙星的药代动力学和组织穿透性。
Pharmacokinetics and tissue penetration of enoxacin.
作者信息
Wise R, Lockley R, Dent J, Webberly M
出版信息
Antimicrob Agents Chemother. 1984 Jul;26(1):17-9. doi: 10.1128/AAC.26.1.17.
Abstract
The pharmacokinetics of the quinolone enoxacin were studied after a 600-mg oral dose was given to each of six male volunteers. The levels of the compound were measured in serum, blister fluid, and urine. Absorption was variable, with peak levels (mean, 3.7 micrograms/ml) being attained between 0.75 and 3.0 h (mean, 1.9 h). The serum elimination half-life was 6.2 h, and 71.6% of the drug was recovered in the urine by 48 h. Enoxacin penetrated blister fluid well, the mean percent penetration being 78.4%.
摘要
给6名男性志愿者每人口服600毫克喹诺酮类药物依诺沙星后，对其药代动力学进行了研究。在血清、水疱液和尿液中测量了该化合物的水平。吸收情况各异，在0.75至3.0小时（平均1.9小时）之间达到峰值水平（平均3.7微克/毫升）。血清消除半衰期为6.2小时，到48小时时，71.6%的药物在尿液中被回收。依诺沙星能很好地渗透到水疱液中，平均渗透百分比为78.4%。
相似文献
1
Pharmacokinetics and tissue penetration of enoxacin.
Antimicrob Agents Chemother. 1984 Jul;26(1):17-9. doi: 10.1128/AAC.26.1.17.
2
The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin.
Infection. 1986;14 Suppl 3:S196-202. doi: 10.1007/BF01667843.
3
The pharmacokinetics and tissue penetration of enoxacin and norfloxacin.
J Antimicrob Chemother. 1984 Sep;14 Suppl C:75-81. doi: 10.1093/jac/14.suppl_c.75.
4
The pharmacokinetics and tissue penetration of ofloxacin.
J Antimicrob Chemother. 1984 Dec;14(6):647-52. doi: 10.1093/jac/14.6.647.
5
The comparative pharmacokinetics of five quinolones.
J Antimicrob Chemother. 1986 Nov;18 Suppl D:71-81. doi: 10.1093/jac/18.supplement_d.71.
6
Pharmacokinetics and tissue penetration of ciprofloxacin.
Antimicrob Agents Chemother. 1983 Nov;24(5):784-6. doi: 10.1128/AAC.24.5.784.
7
Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone.
Antimicrob Agents Chemother. 1987 Feb;31(2):161-3. doi: 10.1128/AAC.31.2.161.
8
Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule.
Rev Infect Dis. 1988 Jan-Feb;10 Suppl 1:S83-9.
9
[Enoxacin concentration in human prostatic tissue].
Hinyokika Kiyo. 1986 Oct;32(10):1471-3.
10
Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).
Antimicrob Agents Chemother. 1996 Jan;40(1):47-9. doi: 10.1128/AAC.40.1.47.
引用本文的文献
1
Inhibitory effects of fluoroquinolone antibiotics on and , blood parasites of veterinary and zoonotic importance.
Infect Drug Resist. 2018 Sep 28;11:1605-1615. doi: 10.2147/IDR.S159519. eCollection 2018.
2
Distribution kinetics of enoxacin and its metabolite oxoenoxacin in excretory fluids of healthy volunteers.
Antimicrob Agents Chemother. 1995 Sep;39(9):2092-7. doi: 10.1128/AAC.39.9.2092.
3
Pharmacokinetics: metabolism and renal excretion of quinolones in man.
Pharm Weekbl Sci. 1986 Feb 21;8(1):29-34. doi: 10.1007/BF01975476.
4
Difloxacin metabolism and pharmacokinetics in humans after single oral doses.
Antimicrob Agents Chemother. 1986 Nov;30(5):689-93. doi: 10.1128/AAC.30.5.689.
5
[Results of treatment of bacterial inflammation of the skin with enoxacin].
Infection. 1986;14 Suppl 3:S217-8. doi: 10.1007/BF01667848.
6
Comparative pharmacokinetics of new quinolones.
Drugs. 1987;34 Suppl 1:21-5. doi: 10.2165/00003495-198700341-00006.
7
Effect of food on enoxacin absorption.
Antimicrob Agents Chemother. 1987 Apr;31(4):638-9. doi: 10.1128/AAC.31.4.638.
8
Efficacy of enoxacin in the treatment of bacterial infections of the skin with regards to photosensitization.
Infection. 1986;14 Suppl 3:S213-6. doi: 10.1007/BF01667847.
9
In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections.
Infection. 1986;14 Suppl 3:S203-8. doi: 10.1007/BF01667844.
10
The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin.
Infection. 1986;14 Suppl 3:S196-202. doi: 10.1007/BF01667843.
本文引用的文献
1
The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics.
J Infect Dis. 1980 Jul;142(1):77-82. doi: 10.1093/infdis/142.1.77.
2
Pharmacokinetics and tissue penetration of ciprofloxacin.
Antimicrob Agents Chemother. 1983 Nov;24(5):784-6. doi: 10.1128/AAC.24.5.784.
3
In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents.
J Antimicrob Chemother. 1984 Mar;13(3):237-44. doi: 10.1093/jac/13.3.237.
4
In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid.
Antimicrob Agents Chemother. 1983 May;23(5):641-8. doi: 10.1128/AAC.23.5.641.
5
The pharmacokinetics and tissue penetration of norfloxacin.
J Antimicrob Chemother. 1984 Jan;13(1):87-92. doi: 10.1093/jac/13.1.87.
6
In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.
Antimicrob Agents Chemother. 1983 Nov;24(5):754-63. doi: 10.1128/AAC.24.5.754.
7
In vitro activity of CI-919 (AT-2266), an oral antipseudomonal compound.
Antimicrob Agents Chemother. 1983 May;23(5):658-63. doi: 10.1128/AAC.23.5.658.
8
Norfloxacin disposition after sequentially increasing oral doses.
Antimicrob Agents Chemother. 1983 Feb;23(2):284-8. doi: 10.1128/AAC.23.2.284.
9
Drug therapy. Clinical Pharmacokinetics (first of two parts).
N Engl J Med. 1975 Oct 2;293(14):702-5. doi: 10.1056/NEJM197510022931406.
Zotero 插件